Nasdaq:US$8.69 (-0.47) | HKEX:HK$13.80 (+0.28) | AIM:£1.59 (-0.08)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.